| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5716 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2946 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1769 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1424 | 2021 |
| Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ... New England Journal of Medicine 384 (20), 1885-1898, 2021 | 1423 | 2021 |
| Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1200 | 2021 |
| ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques N Van Doremalen, T Lambe, A Spencer, S Belij-Rammerstorfer, ... Nature 586 (7830), 578-582, 2020 | 1188 | 2020 |
| Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi, C Dold, M Fuskova, ... Nature medicine 27 (11), 2032-2040, 2021 | 1186 | 2021 |
| Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara J Schneider, SC Gilbert, TJ Blanchard, T Hanke, KJ Robson, CM Hannan, ... Nature medicine 4 (4), 397-402, 1998 | 851 | 1998 |
| Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ... Cell 184 (16), 4220-4236. e13, 2021 | 810 | 2021 |
| Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans H McShane, AA Pathan, CR Sander, SM Keating, SC Gilbert, K Huygen, ... Nature medicine 10 (11), 1240-1244, 2004 | 779 | 2004 |
| Natural selection of hemi-and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria C Ruwende, SC Khoo, RW Snow, SNR Yates, D Kwiatkowski, S Gupta, ... Nature 376 (6537), 246-249, 1995 | 775 | 1995 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 770 | 2021 |
| Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans SJ McConkey, WHH Reece, VS Moorthy, D Webster, S Dunachie, ... Nature medicine 9 (6), 729-735, 2003 | 722 | 2003 |
| Antibody evasion by the P. 1 strain of SARS-CoV-2 W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (11), 2939-2954. e9, 2021 | 682 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 632 | 2021 |
| Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 521 | 2021 |
| Upregulation of TGF-β, FOXP3, and CD4+ CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection M Walther, JE Tongren, L Andrews, D Korbel, E King, H Fletcher, ... Immunity 23 (3), 287-296, 2005 | 494 | 2005 |
| A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity MDJ Dicks, AJ Spencer, NJ Edwards, G Wadell, K Bojang, SC Gilbert, ... PloS one 7 (7), e40385, 2012 | 441 | 2012 |
| Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation KJ Ewer, GA O’Hara, CJA Duncan, KA Collins, SH Sheehy, ... Nature communications 4 (1), 2836, 2013 | 382 | 2013 |
Simon J DraperProfessor of Vaccinology and Translational Medicine, University of Oxfordبريد إلكتروني تم التحقق منه على paediatrics.ox.ac.uk
